Scarica l'app Stockscreener
1.96
2.62%
0.05
Dopo l'orario di chiusura:
1.95
-0.01
-0.51%
Precedente Chiudi:
$1.91
Aprire:
$1.93
Volume 24 ore:
3.30M
Relative Volume:
0.72
Capitalizzazione di mercato:
$84.84M
Reddito:
-
Utile/perdita netta:
$-51.50M
Rapporto P/E:
-0.49
EPS:
-4
Flusso di cassa netto:
$-47.10M
1 W Prestazione:
+53.12%
1M Prestazione:
+49.62%
6M Prestazione:
+11.36%
1 anno Prestazione:
-62.52%
Intervallo 1D:
$1.84
$1.99
Intervallo di 1 settimana:
$1.36
$2.01
Portata 52W:
$0.79
$5.44
Outlook Therapeutics Inc Stock (OTLK) Company Profile
Nome
Outlook Therapeutics Inc
Settore
Industria
Telefono
(609) 619-3990
Indirizzo
111 S. WOOD AVENUE, ISELIN, NJ
Confronta OTLK con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OTLK
Outlook Therapeutics Inc
|
1.96 | 84.84M | 0 | -51.50M | -47.10M | -4.00 |
|
ARGX
Argen X Se Adr
|
914.59 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
203.56 | 43.00B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.03 | 110.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
ONC
Beone Medicines Ltd Adr
|
353.79 | 40.27B | 4.98B | 69.59M | 525.67M | 0.5197 |
|
REGN
Regeneron Pharmaceuticals Inc
|
702.75 | 76.23B | 14.25B | 4.58B | 3.88B | 41.77 |
Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-29 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-08-28 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-12-02 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2024-03-27 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2024-02-15 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2024-01-25 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-12-27 | Aggiornamento | CapitalOne | Equal Weight → Overweight |
| 2023-08-31 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2023-08-31 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-08-30 | Downgrade | BTIG Research | Buy → Neutral |
| 2023-08-30 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-08-30 | Downgrade | CapitalOne | Overweight → Equal Weight |
| 2023-08-30 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-07-13 | Iniziato | CapitalOne | Overweight |
| 2023-04-03 | Iniziato | Guggenheim | Buy |
| 2023-02-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-10-31 | Iniziato | BTIG Research | Buy |
| 2022-09-13 | Iniziato | Chardan Capital Markets | Buy |
| 2019-09-11 | Iniziato | Ladenburg Thalmann | Buy |
| 2019-05-16 | Iniziato | Oppenheimer | Outperform |
| 2019-04-22 | Iniziato | Ascendiant Capital Markets | Buy |
Mostra tutto
Outlook Therapeutics Inc Borsa (OTLK) Ultime notizie
Why Outlook Therapeutics Inc. stock is a must watch in 2025Earnings Summary Report & Safe Capital Growth Stock Tips - newser.com
What analyst consensus implies for Outlook Therapeutics Inc. (41O) stock2025 Institutional Moves & Breakout Confirmation Alerts - newser.com
Will Outlook Therapeutics Inc. (41ON) stock enhance shareholder valueJobs Report & Verified Momentum Stock Ideas - newser.com
How Outlook Therapeutics Inc. stock reacts to Fed rate cutsWeekly Market Report & Technical Pattern Based Signals - newser.com
Will Outlook Therapeutics Inc. (41O) stock beat value stocksMarket Movers & Accurate Buy Signal Notifications - newser.com
Outlook Therapeutics Shares Surge on Key FDA Regulatory Milestone - Ad-hoc-news.de
Is Outlook Therapeutics Inc. stock a smart buy before Fed meetingMarket Risk Analysis & Fast Moving Trade Plans - newser.com
How Outlook Therapeutics Inc. (41O) stock trades under stagflationWeekly Trade Review & Trade Opportunity Analysis Reports - newser.com
Is Outlook Therapeutics Inc. (41ON) stock expanding market penetrationGold Moves & Real-Time Price Movement Reports - newser.com
Is Outlook Therapeutics Inc. (41ON) stock worth buying before Fed actionJuly 2025 Levels & Accurate Intraday Trading Signals - newser.com
Is Outlook Therapeutics Inc. stock a dividend growth opportunity2025 Key Lessons & Step-by-Step Trade Execution Guides - newser.com
Is Outlook Therapeutics Inc. (41ON) stock cheap vs fundamentals2025 Market Overview & Weekly Market Pulse Updates - newser.com
Outlook Therapeutics Inc. stock momentum explainedEarnings Recap Report & Smart Money Movement Tracker - newser.com
Outlook Therapeutics Inc. (OTLK) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Outlook Therapeutics Surges as FDA Greenlights ONS-5010 Resubmission - timothysykes.com
What technical models suggest about Outlook Therapeutics Inc.’s comeback - newser.com
How to interpret RSI for Outlook Therapeutics Inc. stockPortfolio Growth Summary & High Accuracy Swing Entry Alerts - newser.com
Is Outlook Therapeutics Inc. stock cheap at current valuationTrend Reversal & Daily Volume Surge Signals - newser.com
FDA Acceptance Boosts Outlook Therapeutics Shares Significantly - timothysykes.com
Biotech Investor Alert: Outlook Therapeutics Nears Critical FDA Verdict - AD HOC NEWS
H.C. Wainwright Sticks to Its Hold Rating for Outlook Therapeutics (OTLK) - The Globe and Mail
FDA Accepts Outlook Therapeutics’ Resubmission for Eye Drug, Stock Surges - StocksToTrade
FDA Accepts Outlook Therapeutics’ BLA Resubmission for ONS-5010 - timothysykes.com
Outlook Therapeutics Inc Azioni (OTLK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.07%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):